La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Cadrenal Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Cadrenal Therapeutics..

Cadrenal Therapeutics (NASDAQ:CVKD) Azioni, Catena delle Opzioni

Cadrenal Therapeutics

Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics Inc

Nextdoor Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KIND#NYSE">KIND</a>) raises FY2024 sales outlook from $240.14 million to $245.00 million.

News

Guidance

KIND

Nextdoor Holdings Raises FY2024 Sales Guidance from $240.14M to $245.00M

Albemarle Maintains FY24 Outlook Which Are Based On Observed Lithium Market Price Scenarios

Service Properties Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVC#NASDAQ">SVC</a>) reported quarterly earnings of $0.32 per share which missed the analyst consensus estimate of $0.38 by 15.79 percent. The company reported quarterly sales of $491.171 million which missed the analyst consensus estimate of $497.001 million by 1.17 percent. This is a 1.14 percent decrease over sales of $496.825 million the same period last year.

Earnings

Earnings Misses

Service Properties Trust Q3 2024 FFO $0.32 Misses $0.38 Estimate, Sales $491.171M Miss $497.001M Estimate

Faro Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.03 by 600 percent. The company reported quarterly sales of $82.563 million which beat the analyst consensus estimate of $78.972 million by 4.55 percent. This is a 4.90 percent decrease over sales of $86.813 million the same period last year.

Earnings Beats

FARO

Faro Technologies Q3 2024 Adj. EPS $0.21 Beats $0.03 Estimate, Sales $82.563M Beat $78.972M Estimate

Noodles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDLS#NASDAQ">NDLS</a>) lowers FY2024 sales outlook from $495.00 million-505.00 million to $487.00 million-495.00 million.

NDLS

Noodles Lowers FY2024 Sales Guidance from $495.00M-505.00M to $487.00M-495.00M  VS Est.499M

Personalis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.36) by 77.78 percent. This is a 6.67 percent decrease over losses of $(0.60) per share from the same period last year. The company reported quarterly sales of $25.709 million which beat the analyst consensus estimate of $21.324 million by 20.56 percent. This is a 40.89 percent increase over sales of $18.247 million the same period last year.

PSNL

Personalis Q3 2024 GAAP EPS $(0.64) Misses $(0.36) Estimate, Sales $25.709M Beat $21.324M Estimate

Nextdoor Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KIND#NYSE">KIND</a>) sees Q4 sales of $63.000 million vs $62.00 million estimate.

Nextdoor Holdings Sees Q4 Sales $63.000M vs $62.00M Est

2024 EARNINGS GUIDANCE REAFFIRMED
Black Hills reaffirms its guidance issued on Feb. 7, 2024, for 2024 earnings per share available for common stock to be in the range of $3.80 to $4.00, which was based on the following assumptions:
<ul>
<li>Normal weather conditions within our utility service territories including temperatures, precipitation levels and wind conditions;</li>
<li>Normal operations and weather conditions for planned construction, maintenance and/or capital investment projects;</li>
<li>Constructive and timely outcomes of utility regulatory dockets;</li>
<li>No significant unplanned outages at our generating facilities;</li>
<li>Equity issuance of $170 million to $190 million through the at-the-market equity offering program; and</li>
<li>Production tax credits of approximately $18 million associated with wind generation assets.</li>
</ul>
During the first nine months of 2024, Black Hills issued equity within the forecasted range, completed the sale of production tax credits, and mitigated the financial impacts of mild weather and unplanned generation outages.

Black Hills Corp Sees FY24 EPS $3.80-$4.00 Vs $3.92 Est.

Braemar Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHR#NYSE">BHR</a>) reported quarterly AFFO of $(0.24) per share which missed the analyst consensus estimate of $(0.06) by 300 percent. This is a 200 percent decrease over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $148.40 million which missed the analyst consensus estimate of $154.66 million by 4.05 percent. This is a 7.14 percent decrease over sales of $159.80 million the same period last year.

Braemar Hotels & Resorts Q3 2024 AFFO $(0.24) Misses $(0.06) Estimate, Sales $148.40M Miss $154.66M Estimate

BBSI

Barett Business Services Sees FY24 Gross Billings Growth 7%-8%.

AppLovin Sees Q4 2024 Revenue $1.24B-$1.26B; Sees Adj. EBITDA $740M-$760M

SolarEdge Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) reported quarterly losses of $(15.33) per share. This is a 2687.27 percent decrease over losses of $(0.55) per share from the same period last year. The company reported quarterly sales of $260.903 million which missed the analyst consensus estimate of $269.380 million by 3.15 percent. This is a 64.03 percent decrease over sales of $725.305 million the same period last year.

SEDG

SolarEdge Technologies Q3 2024 Adj. EPS $(15.33) Down From $(0.55) YoY, Sales $260.903M Miss $269.380M Estimate

Regional bank stocks surged on Wednesday, marking their strongest one-day performance in four years as investors bet on a more favorable banking sector environment when Donald Trump returns <a href="https://www.benzinga.com/topic/donald-trump">to the White House.</a>
The SPDR S&amp;P Regional Banking ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRE#NYSE">KRE</a>) — which tracks a basket of 147 small- and mid-cap U.S. banks — jumped 13.4%, posting its largest rally since November 2020. Back then, the announcement of the first COVID-19 vaccine sparked a broad market rebound.
In Wednesday's trading, regional banks outshined even the biggest U.S. banks. Financials were the top-performing sector in the S&amp;P 500, with the Financials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) rising 6%. 
Yet regional banks saw an even greater lift, driven by expectations that Trump&#8217;s policies will uniquely benefit smaller, domestic-focused institutions.
The strength in regional banks also fueled a broader rally in small-cap stocks. The Russell 2000 index, which includes a significant portion of regional banks, surged 6% as investor optimism spread across smaller, U.S.-centric companies.
Regional banks are the most representative sector of the Russell 2000 index, which soared by 6% on Wednesday. 
<h4 class="wp-block-heading">Chart: Regional Banks Mark Best Day Since Covid-19 Vaccine Announcement </h4>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="501" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06160718/image-65-1024x501.png" alt="" class="wp-image-633735" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06160718/image-65-1024x501.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06160718/image-65-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06160718/image-65-768x376.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06160718/image-65-1536x752.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06160718/image-65.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h3 class="wp-block-heading">JPMorgan&#8217;s Elian Identifies 7 Tailwinds For Regional Banks</h3>
JPMorgan analyst Anthony Elian sees multiple factors that could fuel a strong performance for regional banks under Trump&#8217;s leadership.
&#8220;We view these results as being favorable for the regional bank sector tied to several tailwinds,&#8221; Elian wrote in a note on Wednesday. 
He highlighted seven main drivers:
<ol>
<li>Increased lending activity – A pro-business and onshoring agenda is expected to boost lending, potentially driving a revival in loan growth across the industry.</li>
<li>Lower corporate taxes – Trump&#8217;s anticipated tax cuts could enhance profitability for regional banks by reducing their tax burden.</li>
<li>Eased regulatory environment – According to Elian, &#8220;a second Trump administration would include an easier backdrop for regulation for the industry,&#8221; which could help banks reduce compliance costs and expand operations.</li>
<li>Uptick in M&amp;A activity – With a favorable regulatory climate, the sector could see an increase in mergers and acquisitions, a trend that was prevalent during Trump's first term and could benefit mid-sized banks seeking growth.</li>
<li>Attractive valuations – Elian noted that regional banks remain undervalued by historical standards, suggesting &#8220;there is still material upside on the table.&#8221;</li>
<li>Steep Treasury yield curve, Fed still in easing mode – With the Treasury yield curve in a steep pattern and the Federal Reserve to keep lowering rates, regional banks could benefit from improved net interest margins (NIMs) and net interest income (NII), boosting their earnings and profitability over time.</li>
<li>Underweight positioning – Elian highlighted that investors are still largely underweight on regional bank stocks, indicating room for increased demand as sentiment shifts.</li>
</ol>
JPMorgan&#8217;s Elian identified a few standout names in the regional banking space. Among his top picks are First Citizens BancShares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>) and Western Alliance Bancorporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>), both of which are well-positioned to take advantage of the expected uptrend in the sector.
<h3 class="wp-block-heading">Trump&#8217;s 2016 Win Offers Historical Context For Sector Rally</h3>
The market's optimism is further bolstered by historical precedent. Regional bank stocks were among the biggest early beneficiaries following Trump's 2016 election victory.
Between Nov. 9, 2016, and Jan. 10, 2017, the KRE ETF surged nearly 20%, significantly outperforming other sectors during that period.
<h4 class="wp-block-heading">Chart: Performance Of Regional Bank ETF (Nov. 9, 2016 &#8211; Jan. 10, 2017) </h4>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="501" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06160352/image-64-1024x501.png" alt="" class="wp-image-633728" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06160352/image-64-1024x501.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06160352/image-64-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06160352/image-64-768x376.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06160352/image-64-1536x752.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06160352/image-64.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/11/41783357/how-did-s-p-500-sectors-perform-during-trumps-first-term-could-this-time-be-different">How Did S&amp;P 500 Sectors Perform During Trump&#8217;s First Term? Could This Time Be Different?</a></li>
</ul>
Image: Midjourney

Sector ETFs

Politics

Markets

Movers

FCNCA

Regional Bank Stocks Notch Strongest Day In 4 Years: Why Analysts Expect 'Several Tailwinds' From Trump Policies

2024 Financial Outlook
Certara is updating its 2024 outlook, and expects the following:
<ul>
<li>Full year 2024 revenue to be in the range of $380 million to $385 million.</li>
<li>Full year adjusted EBITDA to be in the range of $120 million to $124 million.</li>
<li>Full year adjusted diluted earnings per share is expected to be in the range of $0.41 - $0.44.</li>
<li>Fully diluted shares are expected to be in the range of 160 million to 162 million.</li>
</ul>

CERT

Certara Sees FY24 EPS $0.41-$0.44 Vs $0.41 Est.; Revenue $380M-$385M Vs $386.5M Est.

AMC Enter Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.11) by 63.64 percent. The company reported quarterly sales of $1.35 billion which beat the analyst consensus estimate of $1.33 billion by 1.05 percent. This is a 4.12 percent decrease over sales of $1.41 billion the same period last year.

AMC Enter Hldgs Q3 2024 Adj EPS $(0.04) Beats $(0.11) Estimate, Sales $1.35B Beat $1.33B Estimate

Barrett Bus Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBSI#NASDAQ">BBSI</a>) reported quarterly earnings of $0.74 per share which beat the analyst consensus estimate of $0.69 by 7.25 percent. The company reported quarterly sales of $294.278 million which beat the analyst consensus estimate of $287.279 million by 2.44 percent. This is a 7.66 percent increase over sales of $273.328 million the same period last year.

Barrett Bus Servs Q3 2024 GAAP EPS $0.74 Beats $0.69 Estimate, Sales $294.278M Beat $287.279M Estimate

Reaffirming Fiscal Year 2025 Outlook
Kyndryl is reaffirming its outlook for its fiscal year 2025, which runs from April 2024 to March 2025:
<ul>
<li>Adjusted EBITDA margin of at least 16.3%, representing a year-over-year increase of at least 160 basis points.</li>
<li>Adjusted pretax income of at least $460 million, representing a year-over-year increase of at least $295 million.</li>
<li>Constant-currency revenue growth of (2%) to (4%), which now implies fiscal 2025 revenue of $15.2 to $15.5 billion based on recent exchange rates. The Company continues to expect to deliver year-over-year constant-currency revenue growth in the fourth quarter of the fiscal year.</li>
<li>Adjusted free cash flow of approximately $300 million.</li>
</ul>
Forecasted amounts are based on currency exchange rates as of October 2024.

Kyndryl Reaffirming FY25 Revenue Growth Outlook Of (2%) To (4%), Which Now Implies Fiscal 2025 Revenue Of $15.2B-$15.5B Vs $15.27B Est.

EnerSys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENS#NYSE">ENS</a>) reported quarterly earnings of $2.05 per share which missed the analyst consensus estimate of $2.07 by 0.97 percent. The company reported quarterly sales of $883.700 million which missed the analyst consensus estimate of $887.696 million by 0.45 percent. This is a 1.92 percent decrease over sales of $901.000 million the same period last year.

EnerSys Q2 2025 Adj. EPS $2.05 Misses $2.07 Estimate, Sales $883.700M Miss $887.696M Estimate

Coherent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) reported quarterly earnings of $0.74 per share which beat the analyst consensus estimate of $0.61 by 21.31 percent. This is a 362.5 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $1.35 billion which beat the analyst consensus estimate of $1.31 billion by 2.72 percent. This is a 28.02 percent increase over sales of $1.05 billion the same period last year.

COHR

Coherent Q1 2025 Adj EPS $0.74 Beats $0.61 Estimate, Sales $1.35B Beat $1.31B Estimate

Crane NXT Narrows FY24 Adj. EPS From $4.10-$4.35 To $4.22-$4.30 Vs $4.26 Est; Sees Sales Growth 6%-8%

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Cadrenal Therapeutics, Inc. (CVKD – Research Report) today and set a price targ...

Buy Rating Affirmed for Cadrenal Therapeutics on Strong Clinical and Financial Prospects

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Cadrenal Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cvkd-stock-quote/">CVKD</a>) just reported results for the first quarter of 2024.<ul><li>Cadrenal Therapeutics reported earnings per share of -10 cents. This was below the analyst estimate for EPS of -7 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/cvkd-stock-earnings-cadrenal-therapeutics-for-q1-of-2024/">CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q1 2024

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Cadrenal Therapeutics, Inc. (CVKD – Research Report), retaining the price ta...

Optimistic Outlook for Cadrenal Therapeutics with Buy Rating Amidst Anticoagulation Market Shifts

The latest announcement is out from Cadrenal Therapeutics, Inc. (CVKD). At the 2024 Annual Meeting of Cadrenal Therapeutics, Inc., stockholders app...

Cadrenal Therapeutics Enhances Incentives and Adjusts Stock Plan

Cadrenal Therapeutics, Inc. (CVKD) has issued an update. Cadrenal Therapeutics has announced a partnership with Abbott to propel its key trial for ...

Cadrenal Therapeutics Partners with Abbott on Cardiac Trial

Abbott to collaborate with Cadrenal on anticoagulant tecarfarin

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Cadrenal Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cvkd-stock-quote/">CVKD</a>) just reported results for the second quarter of 2024.<ul><li>Cadrenal Therapeutics reported earnings per share of -15 cents. This was below the analyst estimate for EPS of -8 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/cvkd-stock-earnings-cadrenal-therapeutics-for-q2-of-2024/">CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q2 2024

Cadrenal Therapeutics, Inc. ( ($CVKD) ) has shared an announcement. Cadrenal Therapeutics, Inc. has refreshed its investor presentation with detail...

Cadrenal Therapeutics Unveils Phase 3 Trials and Market Strategy

Cadrenal Therapeutics, Inc. ( ($CVKD) ) just unveiled an announcement. Cadrenal Therapeutics, a late-stage biopharmaceutical firm, has successfully...

Cadrenal Therapeutics Raises $5.1 Million for Tecarfarin

Cadrenal Therapeutics (CVKD) has raised gross proceeds of approximately $5.1M through its at-the-market facility, selling an aggregate of 391,243 s...

Comments

Cadrenal Therapeutics

Cadrenal Therapeutics (CVKD) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO